278 related articles for article (PubMed ID: 26953200)
1. Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine.
Khatri A; Dutta S; Dunbar M; Podsadecki T; Trinh R; Awni W; Menon R
Antimicrob Agents Chemother; 2016 May; 60(5):2965-71. PubMed ID: 26953200
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Khatri A; Dutta S; Wang H; Podsadecki T; Trinh R; Awni W; Menon R
Clin Infect Dis; 2016 Apr; 62(8):972-9. PubMed ID: 26740513
[TBL] [Abstract][Full Text] [Related]
3. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection.
Deeks ED
Drugs; 2014 Nov; 74(17):2079-95. PubMed ID: 25352394
[TBL] [Abstract][Full Text] [Related]
4. Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
Kosloski MP; Oberoi R; Wang S; Viani RM; Asatryan A; Hu B; Ding B; Qi X; Kim EJ; Mensa F; Kort J; Liu W
J Infect Dis; 2020 Jan; 221(2):223-231. PubMed ID: 31504702
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
[TBL] [Abstract][Full Text] [Related]
6. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
Kabbara WK; Ramadan WH
J Infect Public Health; 2015; 8(5):409-17. PubMed ID: 26001757
[TBL] [Abstract][Full Text] [Related]
7. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Sabo JP; Kort J; Ballow C; Haschke M; Battegay M; Fuhr R; Girlich B; Schobelock M; Feifel U; Lang B; Li Y; Elgadi M
Clin Infect Dis; 2014 Nov; 59(10):1420-8. PubMed ID: 25091302
[TBL] [Abstract][Full Text] [Related]
8. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
[TBL] [Abstract][Full Text] [Related]
9. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet.
Frampton JE; Croom KF
Drugs; 2006; 66(11):1501-12; discussion 1513-4. PubMed ID: 16906786
[TBL] [Abstract][Full Text] [Related]
10. Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Khatri A; Trinh R; Zhao W; Podsadecki T; Menon R
Antimicrob Agents Chemother; 2016 Oct; 60(10):6244-51. PubMed ID: 27503645
[TBL] [Abstract][Full Text] [Related]
11. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
[TBL] [Abstract][Full Text] [Related]
12. Raltegravir Once-Daily Tablet: A Review in HIV-1 Infection.
Deeks ED
Drugs; 2017 Oct; 77(16):1789-1795. PubMed ID: 29071467
[TBL] [Abstract][Full Text] [Related]
13. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
Stella-Ascariz N; Montejano R; Rodriguez-Centeno J; Alejos B; Schwimmer C; Bernardino JI; Rodes B; Allavena C; Hoffmann C; Gisslén M; de Miguel R; Esteban-Cantos A; Wallet C; Raffi F; Arribas JR;
J Infect Dis; 2018 Oct; 218(10):1523-1530. PubMed ID: 29982509
[TBL] [Abstract][Full Text] [Related]
14. Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection.
El-Sherif O; Khoo S; Solas C
Curr Opin HIV AIDS; 2015 Sep; 10(5):348-54. PubMed ID: 26248122
[TBL] [Abstract][Full Text] [Related]
15. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
Cahn P; Kaplan R; Sax PE; Squires K; Molina JM; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M; Vandekerckhove L; Ruane P; Yazdanpanah Y; Katlama C; Xu X; Rodgers A; East L; Wenning L; Rawlins S; Homony B; Sklar P; Nguyen BY; Leavitt R; Teppler H;
Lancet HIV; 2017 Nov; 4(11):e486-e494. PubMed ID: 28918877
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.
DeJesus E; Saleh S; Cheng S; van der Mey D; Becker C; Frey R; Unger S; Mueck W
Pulm Circ; 2019; 9(2):2045894019848644. PubMed ID: 30997864
[TBL] [Abstract][Full Text] [Related]
18. Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide.
Custodio JM; Chuck SK; Chu H; Cao H; Ma G; Flaherty J; Ling J; Kearney BP
Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971607
[TBL] [Abstract][Full Text] [Related]
19. Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
Mogalian E; Stamm LM; Osinusi A; Brainard DM; Shen G; Ling KHJ; Mathias A
Clin Infect Dis; 2018 Aug; 67(6):934-940. PubMed ID: 29522076
[TBL] [Abstract][Full Text] [Related]
20. Effect of the Anti-retroviral Drugs Efavirenz, Tenofovir and Emtricitabine on Endothelial Cell Function: Role of PARP.
Faltz M; Bergin H; Pilavachi E; Grimwade G; Mabley JG
Cardiovasc Toxicol; 2017 Oct; 17(4):393-404. PubMed ID: 28050758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]